Taro Amagasaki

发表

A phase I study of single-agent BEZ235 special delivery system sachet in Japanese patients with advanced solid tumors

Koichiro Watanabe, K. Shirao, C. Quadt, 2018, Cancer Chemotherapy and Pharmacology.

Evaluation of the dose and efficacy of ruxolitinib in Japanese patients with myelofibrosis

K. Akashi, K. Takenaka, K. Kirito, 2017, International Journal of Hematology.

Assessing the safety and efficacy of ruxolitinib in a multicenter, open-label study in Japanese patients with myelofibrosis

K. Akashi, K. Kirito, N. Komatsu, 2017, International Journal of Hematology.

Safety and efficacy of INC280 in combination with gefitinib (gef) in patients with EGFR-mutated (mut), MET-positive NSCLC: A single-arm phase lb/ll study.

M. Ahn, Yi-long Wu, E. Felip, 2014 .

Ruxolitinib is effective and safe in Japanese patients with hydroxyurea-resistant or hydroxyurea-intolerant polycythemia vera with splenomegaly

M. Hino, K. Kirito, K. Yamauchi, 2018, International Journal of Hematology.

A multinational, open-label, phase 2 study of ruxolitinib in Asian patients with myelofibrosis: Japanese subset analysis

K. Akashi, K. Takenaka, T. Tauchi, 2015, International Journal of Hematology.

A randomized dose-escalation study to assess the safety, tolerability, and pharmacokinetics of ruxolitinib (INC424) in healthy Japanese volunteers

N. Shimada, M. Woo, Asuka Yamamoto, 2013, International Journal of Hematology.

Effect of ruxolitinib therapy on the quality-of-life of Japanese patients with myelofibrosis

K. Akashi, K. Takenaka, K. Kirito, 2018, Current medical research and opinion.

Nilotinib as frontline therapy for patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase: results from the Japanese subgroup of ENESTnd

Y. Kanda, T. Nagai, M. Kurokawa, 2011, International journal of hematology.

Efficacy and safety of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL: a 36-month analysis of a phase I and II study

T. Naoe, T. Nagai, C. Nakaseko, 2012, International Journal of Hematology.

A Multinational, Open-Label Phase 2 Study Of Ruxolitinib In Asian Patients (Pts) With Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (PPV-MF), Or Post–Essential Thrombocythemia MF (PET-MF)

K. Akashi, L. Shih, Jie Jin, 2013 .

Efficacy and safety of ruxolitinib in Asian patients with myelofibrosis

Jun Yu Li, K. Akashi, K. Takenaka, 2015, Leukemia & lymphoma.

Efficacy and safety of omalizumab in an Asian population with moderate‐to‐severe persistent asthma

K. Ohta, T. Miyamoto, Taro Amagasaki, 2009, Respirology.

A Phase I/II study of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL

T. Naoe, H. Tanii, J. Ishikawa, 2009, International journal of hematology.

Assessing the Safety and Efficacy of Ruxolitinib in a Multicenter, Open-Label, Expanded-Access Study in Japanese Patients with Myelofibrosis (MF)

K. Akashi, K. Kirito, N. Komatsu, 2015 .